The proton-pump inhibitor test: Pros and cons

European Journal of Gastroenterology and Hepatology

Volumn 16, Issue 9, 2004, Pages 847-852

  Bruley Des Varannes, Stanislas ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

CLINICAL TRIAL; DOSE RESPONSE; DRUG MEGADOSE; ESOPHAGITIS; ESOPHAGUS PH; GASTROESOPHAGEAL REFLUX; HUMAN; PH MEASUREMENT; PRIORITY JOURNAL; REVIEW; STOMACH ACID SECRETION; TREATMENT OUTCOME;

ANTI-ULCER AGENTS; GASTROESOPHAGEAL REFLUX; HUMANS; PROTON PUMPS;

EID: 4444366229     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200409000-00005     Document Type: Review

References (36)

1. Dent J, Brun J, Fendrick AM, Fennerty MB, Janssens J, Kahrilas PJ, et al. An evidence-based appraisal of reflux disease management: the Genval Workshop Report. Gut 1999; 44 (suppl 2):S1-S16. Report summarising conclusions from an evidence-based workshop that evaluated major clinical strategies for the management of the full spectrum of GORD.
2. Galmiche JP, Bruley des Varannes S. Endoscopy-negative reflux disease. Curr Gastroenterol Rep 2001; 3:206-214.
3. Fass R. Empirical trials in treatment of gastroesophageal reflux disease. Dig Dis 2000; 18:20-26.
4. French-Belgian Consensus Conference on Adult Gastro-oesophageal Reflux Disease 'Diagnosis and Treatment'. Report of a meeting held in Paris, France, on 21-22 January 1999. The Jury of the consensus conference. Eur J Gastroenterol Hepatol 2000; 12:129-137. Conclusions of the French-Belgian consensus conference.
5. Kahrilas PJ, Quigley EM. Clinical esophageal pH recording: a technical review for practice guideline development. Gastroenterology 1996; 110:1982-1996. Detailed review of technical aspects of pH monitoring and its role in the management of patients.
6. Picon L, Bruley des Varannes S, Groupe de Travail sur les Recommandations pour la Pratique de la pHmétrie Oesophagienne. Recommandations pour la pratique de la pHmétrie oesophagienne. Gastroenterol Clin Biol 2000; 24:931-943.
7. Shi G, Bruley des Varannes S, Scarpignato C, Le Rhun M, Galmiche JP. Reflux-related symptoms in patients with normal oesophageal acid exposure to acid. Gut 1995; 37:457-464.
8. Fass R, Fennerty MB, Ofman JJ, Gralnek IM, Johnson C, Camargo E, Sampliner RE. The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain. Gastroenterology 1998; 115:42-49.
9. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, Festen HPM, Jansen EH, Tuynman HARE, et al. Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol 1997; 92:1997-2000.
10. Fass R, Hell R, Sampliner RE, Pulliam G, Graver H, Hartz V, et al. Effect of ambulatory 24-hour esophageal pH monitoring on reflux-provoking activities. Dig Dis Sci 1999; 44:2263-2269. Study showing the influence of pH monitoring on daily activity, food consumption, habits and sleep.
11. Pandolfino JE, Kahrilas PJ, Cisler J, Chapman J. Esophageal pH monitoring using a catheter-free pH-system (Bravo pH system). Gastroenterology 2002; 122:A192.
12. Bruley des Varannes S, Mion F, Ducrotté P, Zerbib F, Denis P, Ponchon T, Galmiche JP. Simultaneous recordings of esophageal acid exposure using conventional esophageal pH monitoring and the Bravo telemetric catheter free system: analysis of concordance. Gastroenterology 2004; 126:A318.
13. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112:1798-1810.
14. Schindlbeck NE, Klauser AG, Voderholzer WA, Müller-Lissner SA. Empiric therapy for gastroesophageal reflux disease. Arch Intern Med 1995; 155:1808-1812.
15. Johnsson F, Weywadt L, Solhaug JH, Hernqvist H, Bengtsson L. One-week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease. Scand J Gastroenterol 1998; 33:15-20.
16. Juul-Hansen P, Rydning A, Ditlef Jacobsen C, Hansen T. High-dose proton pump inhibitors as a diagnostic test of gastro-oesophageal reflux disease in endoscopic-negative patients. Scand J Gastroenterol 2001; 36:806-8410.
17. Bate CM, Riley SA, Chapman RWG, Durnin AT, Taylor MD. Evaluation of omeprazole test as a cost-effective diagnostic test for gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999; 13:59-66.
18. Fass R, Ofman JJ, Gralnek IM, Johnson C, Camargo E, Sampliner RE, Fennerty MB. Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease. Arch Intern Med 1999; 159:2161-2168.
19. Johnsson F, Hatlebakk JG, Klintenberg AC, Roman J, Toth E, Stubberöd A, et al. One-week esomeprazole treatment: an effective confirmatory test in patients with suspected gastro-esophageal reflux disease. Scand J Gastroenterol 2003; 38:354-359. A good study involving a large population, with a pH-monitoring technique including symptom analysis and with a placebo arm.
20. Galmiche JP, Sacher-Huvelin S, Bonnot-Marlier S, Aygalenq P. Valeur diagnostique du test au rabéprazole pour le diagnostic de reflux gastro-oesophagien en médecine générale. Gastroenterol Clin Biol 2003; 27:A80.
21. Juul-Hansen P, Rydning A. Endoscopy-negative reflux disease: what is the value of a proton-pump inhibitor test in everyday clinical practice? Scand J Gastroenterol 2003; 38:1200-1203.
22. Fass R, Ofman JJ, Sampliner RE, Camargo E, Wendel C, Fennerty MB. The omeprazole test is as sensitive as 24-h oesophageal pH monitoring in diagnosing gastro-oesophageal reflux disease in symptomatic patients with erosive oesophagitis. Aliment Pharmacol Ther 2000; 14:389-396.
23. Fass R, Pulliam G, Hayden CW. Patients with non cardiac chest pain (NCCP) receiving an empiric trial of high dose of lansoprazole demonstrate early symptom response: a double blind placebo-controlled study. Gastroenterology 2001; 120:A221.
24. Xia HHX, Lai KC, Lam SK, Hu WHC, Wong NYH, Hui WM, et al. Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with non-cardiac chest pain. Aliment Pharmacol Ther 2003; 17:369-377.
25. Bruley des Varannes S, Levy P, Lartigue S, Dellatolas F, Lemaire M, Galmiche JP. Comparison of lansoprazole with omeprazole on 24-hour intragastric pH, acid secretion and serum gastrin in healthy volunteers. Aliment Pharmacol Ther 1994; 8:309-314.
26. Vaezi MF, Hicks DM, Abelson TI, Richter JE. Laryngeal signs and symptoms and gastroesophageal reflux disease (GERD): a critical assessment of cause and effect association. Clin Gastroenterol Hepatol 2003; 1:333-344. An excellent up-to-date review on the specificity of reflux-related laryngeal manifestations.
27. Vela MF, Camacho-Labato L, Srinivasan R, Tutuian R, Katz PO, Castell DO. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology 2001; 120:1599-1606.
28. B agonist baclofen in patients with symptoms and duodeno-gastro- oesophageal reflux refractory to proton pump inhibitors. Gut 2003; 52:1397-1402.
29. Miner P, Orr W, Filippone J, Jokubaitis L, Sloan S. Rabeprazole in non erosive gastroesophageal reflux disease: a randomized placebo-controlled study. Am J Gastroenterol 2002; 97:1332-1339.
30. Sacher Huvelin S, Gournay J, Amouretti M, Marquis P, Bruley des Varannes S, Galmiche JP. Oesophage acido-sensible: histoire naturelle et retentissement sur la qualité de vie. Comparaison avec le reflux gastro-oesophagien. Gastroenterol Clin Biol 2000; 24:911-916.
31. Gardner JD, Gallo-Torres H, Sloan S, Robinson M, Miner PB. The basis for the decreased response to proton pump inhibitors in gastro-oesophageal reflux disease patients without erosive oesophagitis. Aliment Pharmacol Ther 2003; 18:891-905.
32. Bruley des Varannes S, Gharib H, Bicheler V, Bost R, Bonaz B, Stanescu L, Delchier JC, Bonnot-Marlier S. Effect of low-dose rabeprazole and omeprazole on gastric acidity: results of a double blind, randomised, placebo-controlled, three-way crossover study in healthy subjects. Aliment Pharmacol Ther 2004; 20: In press.
33. Ofman JJ, Dorn GH, Fennerty MB, Fass R. The clinical and economic impact of competing management strategies for gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2002; 16:261-273.
34. Koufman JA. Laryngopharyngeal reflux is different from classic gastro-esophageal reflux disease. Ear Nose Throat J 2002; 81 (suppl 2):7-9.
35. Fass R, Fennerty B, Johnson C, Camargo L, Sampliner RE. Correlation of ambulatory 24-hour esophageal pH monitoring results with symptom improvement in patients with non cardiac chest pain due to gastro-esophageal reflux disease. J Clin Gastroenterol 1999; 28:36-39.
36. Ofman JJ, Gralnek IM, Udani J, Fennerty MB, Fass R. The cost-effectiveness of the omeprazole test in patients with noncardiac chest pain. Am J Med 1999; 107:219-227.